دورية أكاديمية

The Initial Months of Antiretroviral Therapy and Its Influence on AGEs, HMGB1, and sRAGE Levels in Asymptomatic HIV-Infected Individuals.

التفاصيل البيبلوغرافية
العنوان: The Initial Months of Antiretroviral Therapy and Its Influence on AGEs, HMGB1, and sRAGE Levels in Asymptomatic HIV-Infected Individuals.
المؤلفون: Tasca, Karen Ingrid1, Caleffi, Juliana Trindade1, Correa, Camila Renata2, Gatto, Mariana1, Camargo, Caio Cavassan de1, Mendes, Monica Bannwart1, Golim, Marjorie de Assis3, Biasin, Mara4, Souza, Lenice do Rosário de1
المصدر: Mediators of Inflammation. 11/30/2016, p1-9. 9p.
مصطلحات موضوعية: *HIV infections, *THERAPEUTICS, *RECEPTOR for advanced glycation end products (RAGE), *ANTIRETROVIRAL agents, *HIGH mobility group proteins, *COMORBIDITY, *IMMUNOLOGICAL adjuvants
مستخلص: The development of the typical comorbidities of aging which currently affects people living with HIV/AIDS (PLWHA) can be partially ascribed to the persistent immune activation and chronic inflammation characterizing these individuals. The aim of this study was to analyze the effect exerted by combined antiretroviral therapy (cART) administration on plasma levels of HMGB1 (high mobility group box protein-1), AGEs (advanced glycation end products), their soluble receptor sRAGE, cytokines, C-reactive protein (CRP), and some metabolic markers in asymptomatic PLWHA. Analyses were performed longitudinally in 30 PLWHA, before and about 6–12 months after cART initiation. We observed that lower levels of AGEs in post-cART group were accompanied by an increase of CRP and triglyceride levels already in the early months of therapy. Because of the current ever-earlier recommendations to start cART and its prolonged use, these and other markers should be investigated in order to monitor and postpone the appearance of non-AIDS comorbidities in PLWHA. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:09629351
DOI:10.1155/2016/2909576